|
Report Date : |
15.12.2014 |
IDENTIFICATION DETAILS
|
Name : |
INSTITUTO SANITAS |
|
|
|
|
Registered Office : |
Américo
Vespucio 1260, Santiago 8730606, Región Metropolitana |
|
|
|
|
Country : |
|
|
|
|
|
Year of Establishments : |
1920 |
|
|
|
|
Legal Form : |
Sociedad Anónima |
|
|
|
|
Line of Business : |
Engaged in
manufacturing and marketing of pharmaceutical products Subject
product ranges inculdes: · Analgesic · Antiinfectives · Bronchopulmonary · Cardiovascular · Dermatologicos · Gastrointestinal · Genericos · Ginecourologico · Nutrition And Diabetes · Ophtalmic · Insect Repellent |
|
|
|
|
No of Employees : |
300 |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
USD 100 000 |
|
Status : |
Satisfactory |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2014
|
Country Name |
Previous Rating (30.06.2014) |
Current Rating (30.09.2014) |
|
|
a1 |
a1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
|
Source
: CIA |
|
Legal Name: |
INSTITUTO
SANITAS S.A. |
|
Trade Name: |
Instituto
Sanitas |
|
RUT: |
90073000-4 |
|
Date Created: |
1920 |
|
Date
Incorporated: |
01/01/1993 |
|
Legal
Address: |
Américo Vespucio
1260, Santiago 8730606, Región Metropolitana, Chile |
|
Operative
Address: |
Américo
Vespucio 1260, Santiago 8730606, Región Metropolitana, Chile |
|
Telephone: |
(56-2) 2444
6600 |
|
Fax: |
(56-2) 2444 6651 |
|
Legal Form: |
Sociedad Anónima |
|
Email: |
|
|
Registered
in: |
Chile |
|
Website: |
|
|
Manager: |
Manuel Barros |
|
Staff: |
300 |
|
Activity: |
Import, manufacture and distribution
of pharmaceutical products |
|
BANKS |
|
|
Name of the
Bank: |
Banco de Chile |
|
|
The company
does not make its bank information public |
|
HISTORY |
|
|
|
The company
started business in 1920. |
|
PRINCIPAL
ACTIVITY |
|
|
|
The company
is engaged in the manufacture and marketing of pharmaceutical products |
|
Products/Services
description: |
ANALGESIC |
|
Brands: |
Some of their
several trademarks: |
|
Sales are: |
Wholesale |
|
Clients: |
Distributors,
Pharmacies, Hospitals |
|
Suppliers: |
Indukern,
S.A. |
|
Operations area:
|
National |
|
The company
imports from |
Europe, South
America |
|
The company
exports to |
South America |
|
The subject
employs |
300 employees |
|
Payments: |
No Complaints
|
|
|
|
|
LOCATION |
|
|
Headquarters
: |
Américo Vespucio
1260, Santiago 8730606, Región Metropolitana, Chile |
|
Branches: |
The company
does not have branches |
|
Business
Overview: |
Companies
in this industry manufacture and process pharmaceutical products. Demand for pharmaceuticals
is driven by the desire to cure illness and disease. The profitability of
individual companies depends on their ability to discover and market new
drugs. Large companies benefit from their economies of scale in research,
manufacturing, and marketing. Small companies can compete effectively by
specializing in drugs that target one or two specific ailments and by
partnering with larger drugmakers. Drugs are
chemicals with beneficial biological activity. Modern drug development is an
outgrowth of recent research into the specific causes of illness and disease,
coupled with advances in chemistry and industrial technology that allow
scientists to manufacture chemicals to improve these conditions. |
|
|
|
|
GROUP
STRUCTURE AND SUBSIDIARY COMPANIES |
|
|
Listed at the
stock exchange: |
NO |
|
Capital: |
M$ 2.679.860 |
|
Shareholders
%: |
Quilicura
S.A. is one of the major holders. |
|
Management: |
President,
Joaquín Barros Fontaine |
|
Related
Companies: |
Instituto
Sanitas Argentina S.A. |
|
|
|
|
FINANCIAL
INFORMATION |
|
|
|
This is a
private company which does not make its financials public. The following information
has been provided by our outside sources. |
|
|
|
|
YEAR |
2013 |
|
Revenue |
4 700 000 |
|
Cash Flow |
Normal |
|
|
|
|
Imports in US$ |
|
|
Year |
Total |
|
2012 |
US$ 2,895,738 |
|
2011 |
US$ 2,361,627 |
|
2010 |
US$ 2,226,201 |
|
2009 |
US$ 1,505,585 |
|
2008 |
US$ 1,642,203 |
|
2007 |
US$ 1,163,887 |
|
2006 |
US$ 1,727,437 |
|
|
|
|
Exports in US$ |
|
|
Year |
Total |
|
2012 |
US$ 20,471 |
|
2006 |
US$ 46,000 |
|
2005 |
US$ 8,750 |
|
2004 |
US$ 10,300 |
|
2003 |
US$ 4,750 |
|
2002 |
US$ 5,200 |
|
2000 |
US$ 15,639 |
|
LEGAL FILINGS |
|
|
|
|
|
|
There are no
legal/criminal connected to the subject |
|
SUMMARY |
|
|
|
Instituto
Sanitas is a pharmaceutical manufacturer from Chile with almost 100 years of
experience in the market. |
|
RISK
INFORMATION |
|
|
|
|
|
DEBTS |
Controlled |
|
PAYMENTS |
No Complaints
|
|
CASH FLOW |
Good |
|
SUGGESTED
CREDIT LINE |
USD 100 000 |
|
ENTERVIEW |
|
|
NAME |
Cinthia |
|
POSITION |
Administrative |
|
COMMENTS |
She confirmed
address, activity and staff. She refused to confirm more data. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.62.44 |
|
|
1 |
Rs.98.15 |
|
Euro |
1 |
Rs.77.38 |
INFORMATION DETAILS
|
Analysis Done by
: |
RAS |
|
|
|
|
Report Prepared
by : |
MNL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.